A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.

@article{Harris2002APT,
  title={A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.},
  author={Kevin P G Harris and David C. Wheeler and Camilla C Chong},
  journal={Kidney international},
  year={2002},
  volume={61 4},
  pages={1469-74}
}
BACKGROUND Individuals with chronic renal disease are at high risk of cardiovascular morbidity and mortality, and therefore the management of dyslipidemia is particularly important in this patient population. This double-blind randomized study investigated the efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, atorvastatin, in continuous ambulatory peritoneal dialysis (CAPD) patients with dyslipidemia. METHODS Following a two- to four-week baseline… CONTINUE READING